Deals·October 23, 2026 at 11:03 AM EDT·1 source
Roche taps Zymeworks in up to $813M deal for preclinical T cell engager
ZYME -0.8%AMGN
ZYME · last 30 trading days+0.4% since the news
News
Potential deal value$813 million
Upfront payment$55 million
What happened
- Roche is teaming up with Zymeworks for worldwide rights to a preclinical trispecific T cell engager.
- Roche will pay Zymeworks $55 million upfront; the deal could be worth up to $813 million.
- The therapy could compete with Amgen’s Imdelltra, according to Endpoints News.
Upfront payment
$55 million
Potential deal value
$813 million
Why it matters
The transaction expands Roche’s early-stage oncology pipeline and highlights competition in T cell engager therapies. It may matter to healthcare investors tracking licensing economics and competitive positioning in cancer drug development.
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
Timeline
- EarlierOct 18Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress
- EarlierOct 19Mattel Names Peter Griffith Chief Financial Officer, Replacing Paul Ruh
- EarlierOct 23Zymeworks Inc.: Material agreement
- First reported by Endpoints NewsOct 23Roche taps Zymeworks in up to $813M deal for preclinical T cell engager
Who is involved
Roche taps Zymeworks in up to $813M deal for preclinical T ce…RocheZymeworksZYMEAmgenAMGNImdelltra
Company
Sources (1)
- Endpoints NewsOct 23Roche taps Zymeworks in up to $813M deal for preclinical T cell engager
Related
- 3h · #ESMO26: Roche details magnitude of its KRAS G12C inhibitor’s win over rivals in lung cancer trial
- 3h · Roche Drug Outshines Amgen, Bristol Rivals in Lung Cancer Study
- Yesterday · Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer
- Oct 23 · Zymeworks Inc.: Material agreement
- Oct 18 · Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress
- Oct 19 · Mattel Names Peter Griffith Chief Financial Officer, Replacing Paul Ruh
Read more on YouBank
The Newsroom, ranked for your desk
About ninety free sources every ten minutes, one story per event, read for you: bankers, investors, operators and students each get their own desk. Free to start.
- Why it matters to youEvery story matched to your watchlist, your contacts and your pipeline.
- Follow developing storiesAn alert, and a push, the moment a story you follow moves.
- Your briefing, read aloudA few minutes each morning with a chapter per story.
- Brief modeSwipe through the day, a 20-second card each.